Yinhua CSI Innovative Drugs Industry ETF(159992) Targets Third Consecutive Gain as Strategic Positioning of Biomedical Industry Significantly Elevated

NewTimeSpace News - As of 10:13 on March 26, 2026, the Innovative Medicine ETF (159992) rose 0.64%, targeting its third consecutive gain, with its latest price reaching 0.79 yuan. (The stocks listed above are solely index constituents and do not constitute specific investment recommendations.)

In terms of liquidity, the Innovative Medicine ETF recorded an intraday turnover rate of 1.29% and a trading volume of 187 million yuan. Looking at a longer timeframe, as of March 25, the ETF's average daily trading volume reached 556 million yuan over the past year, ranking first among comparable funds.

Regarding fund size, the Innovative Medicine ETF has grown by 1.561 billion yuan over the past three months, representing a significant increase and ranking 1st among 7 comparable funds in terms of new asset inflows. (Data source: Wind)

In terms of fund shares, the Innovative Medicine ETF increased by 64.2 million shares over the past week, achieving substantial growth and ranking 1st among 7 comparable funds in terms of new share additions. (Data source: Wind)

For capital flows, the Innovative Medicine ETF recorded a net inflow of 44.6042 million yuan in the latest session. Looking at a longer timeframe, the ETF has attracted a total of 33.5785 million yuan over the past 5 trading days. (Data source: Wind)

Data indicates continued positioning by leveraged funds. The Innovative Medicine ETF recorded a net margin purchase of 18.6822 million yuan on the previous trading day, with its latest margin balance reaching 599 million yuan. (Data source: Wind)

As of March 25, the Innovative Medicine ETF has gained 10.41% over the past 2 years. In terms of return capability, as of March 25, 2026, since its inception, the ETF has achieved a maximum monthly return of 22.79%, a maximum consecutive rising period of 4 months, a maximum consecutive gain of 53.27%, and an average monthly return of 6.61% during rising months. As of March 25, 2026, the Innovative Medicine ETF has outperformed its benchmark by 0.57% in annualized returns over the past 2 years.

Regarding drawdown, as of March 25, 2026, the Innovative Medicine ETF's relative benchmark drawdown this year was 0.08%.

In terms of fee structure, the Innovative Medicine ETF charges a management fee of 0.50% and a custody fee of 0.05%.

For tracking accuracy, as of March 25, 2026, the Innovative Medicine ETF's tracking error over the past 5 years was 0.037%.

From a valuation perspective, the CSI Innovative Medicine Industry Index tracked by the ETF currently has a price-to-earnings ratio (PE-TTM) of only 43.28x, standing at the 3.04th percentile over the past year, meaning the valuation is lower than 96.96% of the time during the past year, indicating a historically low level.

The Innovative Medicine ETF closely tracks the CSI Innovative Medicine Industry Index, which selects up to 50 most representative listed companies from among those whose main business involves innovative drug research and development as index constituents to reflect the overall performance of innovative medicine industry listed companies.

Guosheng Securities stated that for the pharmaceutical sector, this means the policy positioning of biomedicine is being further upgraded from "emerging track cultivation" to "an important pillar direction for economic growth and industrial upgrading," with innovative medicine, as the core high-value-added segment of the biomedical industry, being the clearest beneficiary.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.